Michael Severino, MD, discusses the approaches for developing "genome writers" at Tessera Therapeutics, where he joined as CEO in 2022, and the advantages of performing in vivo genome editing over ex vivo approaches. Severino explains where the company is in utilizing its genome writing platform to perform edits in vivo on its journey toward the clinic.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.
Produced by Bill Levine
Hosted by Jonathan D. Grinstein, PhD
Music provided by Artem Hramushkin
Audio mixed and mastered by Jason Mack
Hosted on Acast. See acast.com/privacy for more information.